Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Open accessThe DOI matches its Crossref record; 122 of the 125 references it cites were found in a registry or an index.
Abstract
Cancer tissues are composed of cancer cells and the surrounding stromal cells (e.g., fibroblasts, vascular endothelial cells, and immune cells), in addition to the extracellular matrix. Most studies investigating carcinogenesis and the progression, invasion, metastasis, and angiogenesis of cancer have focused on alterations in cancer cells, including genetic and epigenetic changes. Recently, interactions between cancer cells and the stroma have attracted considerable attention, and increasing evidence has accumulated on this. Several researchers have gradually clarified the origins, features, and roles of cancer-associated fibroblasts (CAFs), a major component of the cancer stroma. CAFs function in a similar manner to myofibroblasts during wound healing. We previously reported the relationship between CAFs and angiogenesis. Interleukin-6 (IL-6), a multifunctional cytokine, plays a central role in regulating inflammatory and immune responses, and important roles in the progression, including proliferation, migration, and angiogenesis, of several cancers. We showed that CAFs are an important IL-6 source and that anti-IL-6 receptor antibody suppressed angiogenesis and inhibited tumor-stroma interactions. Furthermore, CAFs contribute to drug-resistance acquisition in cancer cells. The interaction between cancer cells and the stroma could be a potential target for anti-cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, recent studies indicated that CAFs consist of several types of stromal cells that differ in their origin, functions, number, and phenotype [21, 22, 23, 24].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer
Sun, X., Mao, Y., Wang, J., Zu, L., Hao, M., Cheng, G., Qu, Q., Cui, D., Keller, E. T., Chen, X., et al. (2014) · Oncogene · doi:10.1038/onc.2014.158 · Cited by 75
RetractedSun, X., Mao, Y., Wang, J., Zu, L., Hao, M., Cheng, G., Qu, Q., Cui, D., Keller, E. T., CHEN, X., et al. (2014) · Oncogene · doi:10.1038/onc.2014.224 · Cited by 40
RetractedChen, L., Qu, C., Chen, H., Xu, L., Qi, Q., Luo, J., Wang, K., Meng, Z., Chen, Z., Wang, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096177 · Cited by 30
RetractedWarburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“This phenomenon is known as “Warburg effect” [84].”
BackgroundThe distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“proposed the theory that a “tumor is a wound that never heals” [2].”
BackgroundThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Myofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290 · cited 2×
“These myofibroblasts acquire de novo expressed α-SMA, contractile stress fibers, and the ED-A splice variant of fibronectin [5,7].”
BackgroundComplex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 1×
“Proteomic analysis showed a correlation between stromal secretions of hepatocyte growth factor (HGF) and PLX4720 resistance [99].”
BackgroundEvidence that fibroblasts derive from epithelium during tissue fibrosis
Iwano, M., Plieth, D., Danoff, T. M., Xue, C., Okada, H., & Neilson, E. G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215518 · Cited by 1,590
The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A. K., Frank, P. G., Casimiro, M. C., Wang, C., Fortina, P., Addya, S., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10238 · Cited by 1,391
Blood Vessel Formation: What Is Its Molecular Basis?
Folkman, J., & D'Amore, P. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81810-3 · Cited by 1,215
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134 · cited 1×
“Another useful marker for CAFs is fibroblast activation protein (FAP), which is also a useful marker of myofibroblasts [9,10].”
BackgroundCancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression
Hwang, R. F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A., Ji, B., Evans, D. B., & Logsdon, C. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5714 · Cited by 1,099
Identification and characterization of a fibroblast marker: FSP1.
Strutz, F., Okada, H., Lo, C. W., Danoff, T., Carone, R. L., Tomaszewski, J. E., & Neilson, E. G. (1995) · The Journal of cell biology · doi:10.1083/jcb.130.2.393 · Cited by 1,077
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062
Quante, M., Tu, S. P., Tomita, H., Gonda, T., Wang, S. S. W., Takashi, S., Baik, G. H., Shibata, W., DiPrete, B., Betz, K. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.020 · Cited by 1,044
Discovery of Endothelial to Mesenchymal Transition as a Source for Carcinoma-Associated Fibroblasts
Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M., & Kalluri, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-3127 · Cited by 1,011
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892 · cited 4×
“categorized the roles of CAFs in drug resistance, that is, in soluble factor-mediated drug resistance (SFM-DR) and cell adhesion-mediated drug resistance (CAM-DR) [98].”
BackgroundInfluentialKojima, Y., Acar, A., Eaton, E. N., Mellody, K. T., Scheel, C., Ben-Porath, I., Onder, T. T., Wang, Z. C., Richardson, A. L., Weinberg, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013805107 · Cited by 848
Serini, G., Bochaton-Piallat, M.-L., Ropraz, P., Geinoz, A., Borsi, L., Zardi, L., & Gabbiani, G. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.142.3.873 · Cited by 847 · cited 1×
“These myofibroblasts acquire de novo expressed α-SMA, contractile stress fibers, and the ED-A splice variant of fibronectin [5,7].”
BackgroundStromal biology and therapy in pancreatic cancer
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., et al. (2011) · Gut · doi:10.1136/gut.2010.226092 · Cited by 757
Stromal myofibroblasts are drivers of invasive cancer growth
De Wever, O., Demetter, P., Mareel, M., & Bracke, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23925 · Cited by 722
Identification of fibroblast heterogeneity in the tumor microenvironment
Sugimoto, H., Mundel, T. M., Kieran, M. W., & Kalluri, R. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.12.3354 · Cited by 699
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Greenburg, G., & Hay, E. D. (1982) · The Journal of cell biology · doi:10.1083/jcb.95.1.333 · Cited by 674
Stromal cells in tumor microenvironment and breast cancer
Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., & Wang, J. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9415-3 · Cited by 671 · cited 1×
“Recently, an increasing number of studies have examined the relationship between stromal cells, including CAFs, and drug resistance [95–97].”
BackgroundTumor microenvironment: The role of the tumor stroma in cancer
Li, H., Fan, X., & Houghton, J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21159 · Cited by 646
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633 · cited 1×
“The combination of DNA vaccine chemotherapy is considered effective [104].”
BackgroundPark, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36505 · Cited by 586
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance
Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E., Ho, P. L., et al. (2015) · Nature · doi:10.1038/nature14034 · Cited by 578
The role of endothelial-to-mesenchymal transition in cancer progression
Potenta, S., Zeisberg, E., & Kalluri, R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604662 · Cited by 554
Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts
Direkze, N. C., Hodivala-Dilke, K., Jeffery, R., Hunt, T., Poulsom, R., Oukrif, D., Alison, M. R., & Wright, N. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1708 · Cited by 530 · cited 1×
“It was reported that approximately 25% of the myofibroblasts in these pancreatic tumors are donor-derived [40].”
BackgroundComito, G., Giannoni, E., Segura, C. P., Barcellos-de-Souza, P., Raspollini, M. R., Baroni, G., Lanciotti, M., Serni, S., & Chiarugi, P. (2014) · Oncogene · doi:10.1038/onc.2013.191 · Cited by 528
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493 · cited 2×
“inhibition of the anaerobic glycolytic pathway [90].”
BackgroundVascular and interstitial barriers to delivery of therapeutic agents in tumors
Jain, R. K. (1990) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046364 · Cited by 489
Pietras, K., Östman, A., SJÖQUIST, M., Buchdunger, E., Reed, R. K., Heldin, C., & Rubin, K. (2001) · PubMed · Cited by 450
Rapamycin and mTOR kinase inhibitors
Ballou, L. M., & Lin, R. Z. (2008) · Journal of Chemical Biology · doi:10.1007/s12154-008-0003-5 · Cited by 442
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras, K., Rubin, K., Sjöblom, T., Buchdunger, E., Sjöquist, M., Heldin, C., & Östman, A. (2002) · PubMed · Cited by 433
Nagasaki, T., Hara, M., Nakanishi, H., Takahashi, H., Sato, M., & Takeyama, H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.748 · Cited by 385
Self-citationMicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer
Mitra, A. K., Zillhardt, M., Hua, Y., Tiwari, P., Murmann, A. E., Peter, M. E., & Lengyel, E. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0206 · Cited by 371
Tse, J. C., & Kalluri, R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21215 · Cited by 370
Lotti, F., Jarrar, A. M., Pai, R. K., Hitomi, M., Lathia, J., Mace, A., Gantt, G. A., Sukhdeo, K., DeVecchio, J., Vasanji, A., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131195 · Cited by 359
Hu, Y., Yan, C., Mu, L., Huang, K., Li, X., Tao, D., Wu, Y., & Qin, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125625 · Cited by 348
Sherman-Baust, C. A., Weeraratna, A. T., Rangel, L. B. A., Pizer, E. S., Cho, K. R., Schwartz, D. R., Shock, T., & Morin, P. J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00058-8 · Cited by 339
Oxidative stress promotes myofibroblast differentiation and tumour spreading
Toullec, A., Gerald, D., Despouy, G., Bourachot, B., Cardon, M., Lefort, S., Richardson, M., Rigaill, G., Parrini, M., Lucchesi, C., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000073 · Cited by 339
Ishigami, S.-I., Arii, S., Furutani, M., Niwano, M., Harada, T., Mizumoto, M., Mori, A., Onodera, H., & Imamura, M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.688 · Cited by 338
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
Teicher, B., Herman, T., Holden, S., Wang, Y., Pfeffer, M., Crawford, J., & Frei, E. (1990) · Science · doi:10.1126/science.247.4949.1457 · Cited by 327
Smooth‐muscle differentiation in stromal cells of malignant and non‐malignant breast tissues
Sappino, A. ‐., Skalli, O., Jackson, B., Schürch, W., & Gabbiani, G. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410512 · Cited by 325
Li, L., & Bhatia, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1499 · Cited by 293
Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction
Ishii, G., Sangai, T., Oda, T., Aoyagi, Y., Hasebe, T., Kanomata, N., Endoh, Y., Okumura, C., Okuhara, Y., Magae, J., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01544-4 · Cited by 281 · cited 2×
“When the tumor stroma was examined, both bone marrow-derived endothelial cells and α-SMA-positive myofibroblasts were present within and around cancer nests [39].”
BackgroundStructural analysis of endocardial cytodifferentiation
Markwald, R. R., Fitzharris, T. P., & Smith, W. N. A. (1975) · Developmental Biology · doi:10.1016/0012-1606(75)90321-8 · Cited by 265
Martinez-Outschoorn, U. E., Pavlides, S., Whitaker-Menezes, D., Daumer, K. M., Milliman, J. N., Chiavarina, B., Migneco, G., Witkiewicz, A. K., Martinez-Cantarin, M. P., Flomenberg, N., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.12.12048 · Cited by 246
Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β
Stuelten, C. H., Byfield, S. D., Arany, P. R., Karpova, T. S., Stetler-Stevenson, W. G., & Roberts, A. B. (2005) · Journal of Cell Science · doi:10.1242/jcs.02334 · Cited by 238
Jotzu, C., Alt, E., Welte, G., Li, J., Hennessy, B. T., Devarajan, E., Krishnappa, S., Pinilla, S., Droll, L., & Song, Y.-H. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0012-1 · Cited by 236
Weber, C. E., Kothari, A. N., Wai, P. Y., Li, N. Y., Driver, J., Zapf, M. A. C., Franzen, C. A., Gupta, G. N., Osipo, C., Zlobin, A., et al. (2015) · Oncogene · doi:10.1038/onc.2014.410 · Cited by 226
Regulation of Multidrug Resistance in Cancer Cells by Hyaluronan
Misra, S., Ghatak, S., Zoltan-Jones, A., & Toole, B. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300173200 · Cited by 221
R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways
Cao, Y., Cao, R., & Hedlund, E.-M. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0337-z · Cited by 215
Hlatky, L., Tsionou, C., Hahnfeldt, P., & Coleman, C. N. (1994) · PubMed · Cited by 212
Cancer-Associated Fibroblasts Connect Metastasis-Promoting Communication in Colorectal Cancer
Tommelein, J., Verset, L., Boterberg, T., Demetter, P., Bracke, M., & De Wever, O. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00063 · Cited by 207
Wang, D., Huang, H., Kazlauskas, A., & Cavenee, W. K. (1999) · PubMed · Cited by 205
Kharaishvili, G., Simkova, D., Bouchalova, K., Gachechiladze, M., Narsia, N., & Bouchal, J. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-41 · Cited by 197 · cited 1×
“Recently, an increasing number of studies have examined the relationship between stromal cells, including CAFs, and drug resistance [95–97].”
BackgroundSignaling Pathways Governing Tumor Angiogenesis
Sakurai, T., & Kudo, M. (2011) · Oncology · doi:10.1159/000333256 · Cited by 190
Activation of Progelatinase B (proMMP‐9) by Active Collagenase‐3 (MMP‐13)
Knäuper, V., Smith, B., López‐Otin, C., & Murphy, G. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00369.x · Cited by 188
STC1 Expression By Cancer-Associated Fibroblasts Drives Metastasis of Colorectal Cancer
Peña, C., Céspedes, M. V., Lindh, M. B., Kiflemariam, S., Mezheyeuski, A., Edqvist, P.-H., Hägglöf, C., Birgisson, H., Bojmar, L., Jirström, K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1875 · Cited by 181
Tenascin-C and integrins in cancer
Yoshida, T., Akatsuka, T., & Imanaka-Yoshida, K. (2015) · Cell Adhesion & Migration · doi:10.1080/19336918.2015.1008332 · Cited by 178
The role of endothelial-mesenchymal transition in development and pathological process
Lin, F., Wang, N., & Zhang, T. (2012) · IUBMB Life · doi:10.1002/iub.1059 · Cited by 177 · cited 2×
“induced [54–56].”
BackgroundAdipocyte is a non-trivial, dynamic partner of breast cancer cells
Tan, J., Buache, E., Chenard, M.-P., Dali-Youcef, N., & Rio, M.-C. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.113365jt · Cited by 171
Wikberg, M. L., Edin, S., Lundberg, I. V., Van Guelpen, B., Dahlin, A. M., Rutegård, J., Stenling, R., Öberg, Å., & Palmqvist, R. (2013) · Tumor Biology · doi:10.1007/s13277-012-0638-2 · Cited by 171
Fibroblast-mediated drug resistance in cancer
Paraiso, K. H. T., & Smalley, K. S. M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.018 · Cited by 163
Hazlehurst, L. A., & Dalton, W. S. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013156407224 · Cited by 162
Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target
Togo, S., Polanska, U., Horimoto, Y., & Orimo, A. (2013) · Cancers · doi:10.3390/cancers5010149 · Cited by 156
Hematopoietic origin of fibroblasts/myofibroblasts: its pathophysiologic implications
Ogawa, M., LaRue, A. C., & Drake, C. J. (2006) · Blood · doi:10.1182/blood-2006-04-016600 · Cited by 150
Heterogeneity of stromal fibroblasts in tumor
Orimo, A., & Weinberg, R. A. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.4.4255 · Cited by 143
Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Smith, N. R., Baker, D., Farren, M., Pommier, A., Swann, R., Wang, X., Mistry, S., McDaid, K., Kendrew, J., Womack, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1637 · Cited by 136
Fiaschi, T., Giannoni, E., Taddei, L., Cirri, P., Marini, A., Pintus, G., Nativi, C., Richichi, B., Scozzafava, A., Carta, F., et al. (2013) · Cell Cycle · doi:10.4161/cc.24902 · Cited by 135
Yuan, J., Liu, M., Yang, L., Tu, G., Zhu, Q., Chen, M., Cheng, H., Luo, H., Fu, W., Li, Z., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0579-y · Cited by 125
Periostin Is Expressed in Pericryptal Fibroblasts and Cancer-associated Fibroblasts in the Colon
Kikuchi, Y., Kashima, T. G., Nishiyama, T., Shimazu, K., Morishita, Y., Shimazaki, M., Kii, I., Horie, H., Nagai, H., Kudo, A., et al. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.951061 · Cited by 125
Johansson, A.-C., Ansell, A., Jerhammar, F., Lindh, M. B., Grénman, R., Munck-Wikland, E., Östman, A., & Roberg, K. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0030 · Cited by 124
The plasticity of human breast carcinoma cells is more than epithelial to mesenchymal conversion.
PETERSEN, O. W., Nielsen, H. L., Guðjónsson, Þ., Villadsen, R., Rønnov‐Jessen, L., & Bissell, M. J. (2001) · Breast Cancer Research · doi:10.1186/bcr298 · Cited by 123
The Role of Stromal Myofibroblast and Extracellular Matrix in Tumor Angiogenesis
Vong, S., & Kalluri, R. (2011) · Genes & Cancer · doi:10.1177/1947601911423940 · Cited by 123
Targeting cancer cell metabolism in pancreatic adenocarcinoma
Cohen, R., Neuzillet, C., Tijeras-Raballand, A., Faivre, S., de Gramont, A., & Raymond, E. (2015) · Oncotarget · doi:10.18632/oncotarget.4160 · Cited by 120
Akt–Girdin Signaling in Cancer-Associated Fibroblasts Contributes to Tumor Progression
Yamamura, Y., Asai, N., Enomoto, A., Kato, T., Mii, S., Kondo, Y., Ushida, K., Niimi, K., Tsunoda, N., Nagino, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1317 · Cited by 120
Dimanche‐Boitrel, M. T., Vakaet, L., Pujuguet, P., Chauffert, B., Martin, M. S., Hammann, A., Van Roy, F., Mareel, M., & Martin, F. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560410 · Cited by 119
Amornsupak, K., Insawang, T., Thuwajit, P., O-Charoenrat, P., Eccles, S. A., & Thuwajit, C. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-955 · Cited by 114
Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle
Motrescu, E. R., & Rio, M.-C. (2008) · bchm · doi:10.1515/bc.2008.110 · Cited by 114
Jotzu, C., Alt, E., Welte, G., Li, J., Hennessy, B. T., Devarajan, E., Krishnappa, S., Pinilla, S., Droll, L., & Song, Y.-H. (2010) · Analytical Cellular Pathology · doi:10.1155/2010/695162 · Cited by 114
Torres, S., Garcia-Palmero, I., Herrera, M., Bartolomé, R. A., Peña, C., Fernandez-Aceñero, M. J., Padilla, G., Peláez-García, A., Lopez-Lucendo, M., Rodriguez-Merlo, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3096 · Cited by 113
Angelucci, C., Maulucci, G., Lama, G., Proietti, G., Colabianchi, A., Papi, M., Maiorana, A., De Spirito, M., Micera, A., Balzamino, O. B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050804 · Cited by 111
Insidious Changes in Stromal Matrix Fuel Cancer Progression
Miles, F. L., & Sikes, R. A. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0535 · Cited by 111
De Boeck, A., Hendrix, A., Maynard, D., Van Bockstal, M., Daniëls, A., Pauwels, P., Gespach, C., Bracke, M., & De Wever, O. (2013) · PROTEOMICS · doi:10.1002/pmic.201200179 · Cited by 105
Dohi, O., Ohtani, H., Hatori, M., Sato, E., Hosaka, M., Nagura, H., Itoi, E., & Kokubun, S. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03399.x · Cited by 104
Giulianelli, S., Cerliani, J. P., Lamb, C. A., Fabris, V. T., Bottino, M. C., Gorostiaga, M. A., Novaro, V., Góngora, A., Baldi, A., Molinolo, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23802 · Cited by 98
Kitadai, Y., Sasaki, T., Kuwai, T., Nakamura, T., Bucana, C. D., Hamilton, S. R., & Fidler, I. J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22229 · Cited by 95
Taguchi, A., Kawana, K., Tomio, K., Yamashita, A., Isobe, Y., Nagasaka, K., Koga, K., Inoue, T., Nishida, H., Kojima, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089605 · Cited by 84
Autophagy, Warburg, and Warburg Reverse Effects in Human Cancer
González, C. D., Álvarez, S., Ropolo, A., Rosenzvit, C., Bagnes, M. F. G., & Vaccaro, M. I. (2014) · BioMed Research International · doi:10.1155/2014/926729 · Cited by 82
The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis
Sukowati, C. H. C., Anfuso, B., Crocè, L. S., & Tiribelli, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1196-y · Cited by 79
Characterization of Transplanted Green Fluorescent Protein+ Bone Marrow Cells into Adipose Tissue
Tomiyama, K., Murase, N., Stolz, D. B., Toyokawa, H., O'Donnell, D. R., Smith, D. M., Dudas, J. R., Rubin, J. P., & Marra, K. G. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0567 · Cited by 76
Vlahovic, G., Rabbani, Z. N., Herndon, J. E., Dewhirst, M. W., & Vujaskovic, Z. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603366 · Cited by 76
Mentlein, R., Hattermann, K., Hemion, C., Jungbluth, A. A., & Held-Feindt, J. (2011) · Biological Chemistry · doi:10.1515/bc.2010.119 · Cited by 75
Gorchs, L., Hellevik, T., Bruun, J.-A., Camilio, K.-A., Al-Saad, S., Stuge, T.-B., & Martinez-Zubiaurre, I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00087 · Cited by 71
WEN, S., NIU, Y., YEH, S., & CHANG, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3060 · Cited by 63
Sumida, T., Kitadai, Y., Shinagawa, K., Tanaka, M., Kodama, M., Ohnishi, M., Ohara, E., Tanaka, S., Yasui, W., & Chayama, K. (2011) · International Journal of Cancer · doi:10.1002/ijc.25812 · Cited by 60
Kharaziha, P., Rodriguez, P., Li, Q., Rundqvist, H., Björklund, A.-C., Augsten, M., Ullén, A., Egevad, L., Wiklund, P., Nilsson, S., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.1 · Cited by 59
Hematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment
Xiong, Y., McDonald, L. T., Russell, D. L., Kelly, R. R., Wilson, K. R., Mehrotra, M., Soloff, A. C., & LaRue, A. C. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i2.253 · Cited by 55
Hematopoietic stem cell derived carcinoma-associated fibroblasts: a novel origin.
McDonald, L. T., & LaRue, A. C. (2012) · PubMed · Cited by 52
Al‐Ansari, M. M., & Aboussekhra, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090907 · Cited by 49
Watanabe-Takano, H., Takano, K., Hatano, M., Tokuhisa, T., & Endo, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127888 · Cited by 42
The cancer-associated fibroblasts and drug resistance.
Xy, L., Sq, H., & Xiao, L. (2015) · PubMed · Cited by 42
Massani, M., Stecca, T., Fabris, L., Caratozzolo, E., Ruffolo, C., Furlanetto, A., MORTON, S., Cadamuro, M., Strazzabosco, M., & Bassi, N. (2013) · Oncology Reports · doi:10.3892/or.2013.2568 · Cited by 41
Overexpression of Caveolin-1 in Cancer-Associated Fibroblasts Predicts Good Outcome in Breast Cancer
Wang, S.-W., Xu, K.-L., Ruan, S.-Q., Zhao, L., & Chen, L. (2012) · Breast Care · doi:10.1159/000345464 · Cited by 30
Hu, C., Wang, Z., Zhai, L., Miling, Y., Shan, L., Chai, C., Liu, M., & Wang, L. (2012) · Oncology Letters · doi:10.3892/ol.2012.1023 · Cited by 29
Physical barriers to drug delivery in tumors
Curti, B. D. (1993) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(93)90004-n · Cited by 27
Hosein, A. N., Livingstone, J. M., Buchanan, M., Reid, J. F., Hallett, M. T., & Basik, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1117-0 · Cited by 24
Wang, M., Wu, C., Pan, J.-Y., Zheng, W.-W., Cao, X., & Fan, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117405 · Cited by 19
Liu, Z., Fang, J., Xiao, Y., Zhao, Y., Cui, R., Hu, F., & Xu, Q. (2015) · PubMed · Cited by 18
Lin, M. F., Lin, H.-Z., Ma, S., Ji, P., Xie, D., & Yu, J.-X. (2010) · Medical Oncology · doi:10.1007/s12032-010-9427-1 · Cited by 16
Fabris, V. T., Sahores, A., Vanzulli, S. I., Colombo, L. L., Molinolo, A., Lanari, C., & Lamb, C. A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-293 · Cited by 15
(2014) · Receptors & Clinical Investigation · doi:10.14800/rci.202 · Cited by 12
Cited by
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Arneth, B. (2019) · Medicina · doi:10.3390/medicina56010015 · Cited by 1,250
The Acidic Tumor Microenvironment as a Driver of Cancer
Boedtkjer, E., & Pedersen, S. F. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034627 · Cited by 1,223
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Metadata
- Authors
- Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H.
- Affiliations
- Nagoya City University (JP)
- Corresponding author
- Hara, Masayasu
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2015-12-11
- Volume
- 7
- Issue
- 4
- Pages
- 2443-2458
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC4695902
- OpenAlex
- W2190528488
- Cited by
- 774
- References
- 125
- Citations by year
- 2026: 29 · 2025: 42 · 2024: 61 · 2023: 71 · 2022: 83 · 2021: 103 · 2020: 121 · 2019: 104 · 2018: 87 · 2017: 49 · 2016: 21
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- cancer-associated fibroblasts, tumor microenvironment, tumor stroma, tumor-stroma interactions, angiogenesis, interleukin-6, IL-6 receptor, myofibroblasts, drug resistance, tumor progression, cancer therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.